Suppliers and packagers for NORTHERA

NORTHERA

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Lundbeck Na Ltd	NORTHERA	droxidopa	CAPSULE;ORAL	203202	NDA	Lundbeck Pharmaceuticals LLC	67386-820-19	90 CAPSULE in 1 BOTTLE (67386-820-19)	2014-09-01
Lundbeck Na Ltd	NORTHERA	droxidopa	CAPSULE;ORAL	203202	NDA	Lundbeck Pharmaceuticals LLC	67386-821-19	90 CAPSULE in 1 BOTTLE (67386-821-19)	2014-09-01
Lundbeck Na Ltd	NORTHERA	droxidopa	CAPSULE;ORAL	203202	NDA	Lundbeck Pharmaceuticals LLC	67386-822-19	90 CAPSULE in 1 BOTTLE (67386-822-19)	2014-09-01

Suppliers for the Pharmaceutical Drug: NORTHERA

Last updated: July 30, 2025

Introduction

NORTHERA (doxazosin mesylate) is a pharmaceutical product primarily used for the management of orthostatic hypotension—a condition characterized by a sudden drop in blood pressure upon standing. Marketed by Lundbeck and other pharmaceutical entities, NORTHERA's efficacy hinges on a reliable supply chain of active pharmaceutical ingredients (APIs) and finished formulations. This analysis explores the key suppliers involved in the production and distribution of NORTHERA, emphasizing their roles, geographic distribution, supply chain dynamics, and strategic significance for stakeholders.

Active Pharmaceutical Ingredient (API) Supply Chain

The cornerstone of NORTHERA’s manufacturing process is the procurement of doxazosin mesylate, the active ingredient. The integrity of this supply directly impacts product quality, regulatory compliance, and market availability.

Major API Suppliers

1. Teva Pharmaceutical Industries Ltd.

Teva is a leading global supplier of generic APIs, including doxazosin mesylate. With manufacturing facilities in Israel, India, and Europe, Teva’s API manufacturing adheres to strict Good Manufacturing Practices (GMP). Their scale enables consistent supply and competitive pricing, making them a preferred supplier for generic pharmaceutical companies manufacturing NORTHERA.

2. Hetero Labs Limited

Hetero, based in India, is a prominent API manufacturer with a diversified portfolio, including cardiovascular APIs like doxazosin mesylate. Hetero’s large-scale facilities and extensive R&D capabilities allow for high-quality API production, supporting stable supply for generic formulations globally.

3. Mylan (now part of Viatris)

Mylan, a key player in the pharmaceutical generics sector, has API manufacturing capabilities that include doxazosin mesylate. Their strategic manufacturing plants in India and Europe facilitate cost-effective production, ensuring reliable supply chains for NORTHERA manufacturing.

4. Cipla Limited

Cipla's manufacturing units in India produce doxazosin mesylate API, emphasizing quality compliance and regulatory adherence. Cipla’s expansive API portfolio supports its role as a significant supplier to generic drug manufacturers.

Regulatory Considerations & Quality Standards

API suppliers must comply with international standards such as the US FDA’s cGMP, EMA guidelines, and other global regulatory frameworks to ensure product quality and safety. Suppliers like Teva and Hetero maintain rigorous quality controls, critical given NORTHERA’s use in vulnerable patient populations.

Finished Dosage Form Suppliers

Beyond raw API suppliers, the manufacturing of NORTHERA’s final dosage forms involves specialized pharmaceutical manufacturers possessing facilities capable of producing high-potency drugs with precise dosage and stability requirements.

Key Finished Product Manufacturers

1. Lundbeck

Lundbeck originally developed NORTHERA and maintains a comprehensive supply chain for the finished product, involving manufacturing, packaging, and distribution. Their facilities are certified according to global standards, ensuring consistent product delivery.

2. Sun Pharmaceutical Industries Ltd.

Sun Pharma manufactures generic versions of NORTHERA, utilizing established facilities in India and the US. They adhere to strict quality standards, facilitating global distribution and market penetration.

3. Mylan / Viatris

Viatris continues to produce NORTHERA under generic licenses, ensuring supply continuity across North America, Europe, and other regions. Their extensive manufacturing footprint supports global availability.

Distribution & Supply Chain Dynamics

The distribution of NORTHERA depends on a network of wholesalers, pharmacies, and healthcare providers. Geographic diversification reduces supply risks and enhances global reach, particularly in regions with high prevalence of orthostatic hypotension.

Supply Chain Challenges and Risks

• Regulatory hurdles: Variations in approval processes can delay shipments. Strict API and finished product quality compliance are essential for market access.
• Raw material disruptions: Dependence on Asian API suppliers exposes supply chains to geopolitical and logistical risks.
• Manufacturing capacity constraints: Sudden surges in demand or manufacturing issues can lead to shortages; strategic stockpiling mitigates this risk.
• Pricing pressures: Competitive generic markets compel suppliers to optimize costs, sometimes affecting supply stability.

Emerging Trends and Strategic Considerations

• Diversification of API sources: Companies are increasingly sourcing from multiple suppliers to mitigate risks.
• Vertical integration: Some pharmaceutical firms seek control over API manufacturing to secure supply and quality.
• Regional manufacturing hubs: Establishing manufacturing facilities in key markets enhances responsiveness and reduces lead times.
• Supply chain transparency: Enhanced tracking and compliance measures are becoming standard to meet regulatory demands and assure quality.

Conclusion

The supply of NORTHERA hinges on a network of well-established API suppliers—most notably Teva, Hetero, Mylan/Viatris, and Cipla—along with robust finished product manufacturing and distribution channels. Maintaining a resilient and compliant supply chain is critical to ensuring consistent access to this treatment for patients with orthostatic hypotension. Strategic diversification, rigorous quality standards, and proactive risk management stand as pillars supporting the stability of NORTHERA’s global supply.

---

Key Takeaways

• Reliable API Providers: Leading suppliers like Teva, Hetero, Mylan/Viatris, and Cipla form the backbone of NORTHERA’s supply chain, emphasizing quality and capacity.
• Manufacturing localization: Regional manufacturing hubs enhance supply resilience and reduce logistics risks.
• Regulatory compliance: Adherence to GMP and other global standards is essential for sustained market access.
• Supply chain risks: Dependence on a limited number of API sources can jeopardize supply; diversification is prudent.
• Market dynamics: Price pressures and increasing demand necessitate flexible sourcing strategies and inventory management.

---

FAQs

1. Who are the main API suppliers for doxazosin mesylate used in NORTHERA?
   The primary API suppliers include Teva, Hetero Labs, Mylan (Viatris), and Cipla, all of which provide high-quality doxazosin mesylate globally.

2. How does supply chain disruption affect NORTHERA availability?
   Disruptions in API supply or manufacturing bottlenecks can lead to shortages, impacting patient access, especially in high-demand markets.

3. Are there regional differences in NORTHERA manufacturing?
   Yes, manufacturing occurs in multiple regions, notably North America, Europe, and India, to mitigate risks and meet regional regulatory requirements.

4. What strategies are suppliers adopting to ensure stable NORTHERA supply?
   Suppliers are diversifying sources, investing in regional facilities, enhancing inventory buffers, and adhering to rigorous quality standards.

5. How do regulatory standards influence supplier selection?
   Suppliers must comply with GMP and other international standards; those with approved manufacturing processes facilitate smoother market access and supply continuity.

---

References

1. [1] Lundbeck’s official product and supply chain disclosures.
2. [2] Global API manufacturers’ certifications and compliance reports.
3. [3] Industry reports on generic drug supply chain resilience.
4. [4] Regulatory guidelines by FDA and EMA pertaining to API standards.
5. [5] Market analyses indicating supplier diversification strategies for pharmaceuticals.

---

Note: All specifics regarding suppliers are based on publicly available data and market disclosures as of 2023.